The successful implementation of tyrosine kinase inhibitors (TKIs) for the treatment of
chronic myeloid leukemia (CML) remains a flagship for molecularly targeted therapy in …

This chapter summarizes our knowledge regarding the molecular biology of chronic myeloid
leukemia (CML) and its treatment modalities using the breakpoint cluster region‐v‐abl …

Leukemias have traditionally served as model systems for research on neoplasia because
of the easy availability of cell material from blood and marrow for diagnosis, monitoring and …

Chronic myeloid leukemia (CML) is characterized by the Philadelphia translocation that
fuses BCR sequences from chromosome 22 upstream of the ABL gene on chromosome 9 …

Chronic myeloid leukemia (CML) is the prototype cytogenetic malignancy. Even before the
development of basic G-and R-banding techniques, CML was found to be associated with a …

Molecular abnormalities caused by the hybrid Bcr-Abl gene are causally associated with the
development and progression of Philadelphia chromosome–positive (Ph+) chronic …

Chronic myeloid leukemia (CML) is a clonal myeloproliferative disease characterized by a
reciprocal translocation between long arms of chromosomes 9 and 22 t (9; 22) that …

The development of BCR/ABL1 tyrosine kinase inhibitors (TKIs) over the past 20 years has
dramatically improved the outcomes for patients with every stage of Philadelphia …

The identification of the Philadelphia chromosome in cells from individuals with chronic
myelogenous leukemia (CML) led to the recognition that the BCR-ABL tyrosine kinase …

The well‐established molecular pathogenesis of chronic myelogenous leukemia (CML) and
its consequences for laboratory testing and clinical management illustrate a classic …